Avecho Biotechnology (ASX:AVE) announced a milestone in its clinical development program, completing recruitment for the interim analysis cohort in its pivotal Phase 3 trial evaluating a TPM-enhanced cannabidiol capsule for treating insomnia.
According to the release, the company has enrolled approximately 210 participants required for this crucial check-in.
The interim analysis is designed to provide the first indication of the product's efficacy, de-risk the program moving forward, and confirm the exact number of participants required to complete the trial.
"Interim analysis results anticipated in June – a major value-defining milestone for Avecho's pivotal Phase 3 insomnia program," the company stated in its highlights.
The study aims to support the registration of the CBD capsule with the Therapeutic Goods Administration, targeting the unique Australian over-the-counter pathway.
Early forecasts indicate the Australian OTC CBD market could exceed US$125 million per year, while the global insomnia market was valued at US$5.22 billion in 2024.
Commercially, Avecho has already secured a major partnership for the Australian market with Sandoz, which includes up-front payments, milestone payments totaling US$16 million prior to first commercial sales, and tiered royalties of 14-19% on net sales.
Furthermore, Avecho is actively in discussions with potential partners to license the product in regions outside of Australia, furthering its global commercialisation strategy.
At the time of reporting, Avecho Biotechnology's share price was $0.10.